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Short-term costs of conventional vs laparoscopic assisted surgery
in patients with colorectal cancer (MRC CLASICC trial)
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and Cancer Research, University of Leeds, Leeds, UK; 4Academic Unit of Surgery, St James’s University Hospital, Leeds, UK; 5Academic Unit of Pathology,
Leeds Institute of Molecular Medicine, Epidemiology and Cancer Research, University of Leeds, Leeds, UK
The short-term clinical results of the CLASICC trial indicated that clinical outcomes were similar between laparoscopic and open
approaches. This study presents the short-term (3 month) cost analysis undertaken on a subset of patients entered into the
CLASICC trial (682 of 794 patients). As expected the costs associated with the operation were higher in the 452 patients
randomised to laparoscopic surgery (lap) compared with the 230 randomised to open procedure (open), d1703 vs d1386. This was
partially offset by the other hospital (nontheatre) costs, which were lower in the lap group (d2930 vs d3176). The average cost to
individuals for reoperations was higher in the lap group (d762 vs d553). Overall costs were slightly higher in the lap group (d6899 vs
d6631), with mean difference of d268 (95%CI 689 to 1457). Sensitivity analysis made little difference to these results. The cost of
rectal surgery was higher than for colon, for lap (d8259 vs d5586) and open procedures (d7820 vs d5503). The short-term cost
analysis for the CLASICC trial indicates that the costs of either laparoscopic or open procedure were similar, lap surgery costing
marginally more on average than open surgery.
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The last 20 years have seen major improvements in survival
following colorectal cancer as a consequence of advances in early
diagnosis, improved chemotherapy and radiotherapy and ad-
vances in surgical technique (Hayne et al, 2001). The application of
laparoscopic surgery to colorectal disease started in the early
1990s, and was instigated as a means of offering patients a more
rapid recovery, fewer complications and shorter hospital stay
(Jacobs et al, 1991). Conversely, issues have arisen with regard to
the high proportion of patients who require a conversion to an
open procedure, and the generally longer theatre time required
with costs associated with them. However, despite advocates of this
technique, few have been subjected to randomised controlled
clinical trials of therapy (Stage et al, 1997; Hewett et al, 1998; Lacy
et al, 2002). Nonrandomised studies have examined cost, some of
which have indicated lower costs with laparoscopic surgery (Bokey
et al, 1996; Philipson et al, 1997), while others have found the
results to be equivocal (Falk et al, 1993; Bergamaschi and Arnaud,
1997; Joo et al, 1998; Khalili et al, 1998; Young-Fadok et al, 2001).
The Conventional vs Laparoscopic Surgery in Colorectal Cancer
(CLASICC) trial, is a UK multicentre pragmatic trial, which
randomised patients between July 1996 and July 2002 to either
laparoscopic surgery or an open procedure. The trial was designed
to randomise patients to laparoscopic or open surgery (Stead et al,
2000). Details of the overall trial design and short-term clinical
outcomes are reported elsewhere (Guillou et al, 2005). In brief, the
trial was designed to study clinical end points of survival and
disease-free interval. A total of 794 patients from 27 centres (32
surgeons) provided informed consent and were randomised to
laparoscopic (526 patients) or open surgery (268 patients) in a
ratio of 2 : 1, with stratification by surgeon, proposed site of
operation, presence of liver metastases and preoperative radio-
therapy administration. Patients with both colon (413 patients)
and rectal (381 patients) cancer were included in this trial.
The shortterm end points of this trial indicated similar results
between the randomised groups in respect of positive resection
margins, proportion of patients with Dukes’ C tumours and in-
hospital mortality (Guillou et al, 2005). Secondary short-term end
points of surgical complication rates (intraoperatively and up to 30
days and 3 months postoperatively), transfusion requirements and
quality of life up to 3 months were also similar between groups.
The purpose of the current paper is to report on the short-term
cost implications of either laparoscopic or open resection for
patients with colorectal cancer in the CLASICC trial.
METHODS
The cost analysis in this trial was undertaken from the perspective
of the UK National Health Service, with analysis undertaken up to
three months post operation. Information on resource usage was
provided at the individual patient level.
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Patients for this part of the trial were included on the basis that
they provided written informed consent to participate in the
quality of life/health economics sub-study of the trial. This was a
subset of the total patient group (n¼ 682) Patients who did not
give this consent, or where details of the actual operative
procedure were missing at the time of analysis, were not included.
Detailed theatre resource use was undertaken in a subgroup of
these eligible patients, with the aim to recruit 10 patients
randomised to the laparoscopic procedure and 10 patients to the
open procedure from each recruiting surgeon.
Theatre use
Theatre usage was determined on the basis of information
recorded by the surgeons in the immediate postoperative period.
Theatre time was calculated in the subgroup as the time between
first incision to the time that the dressing was applied to the
surgical wound. Theatre time for patients not in the sample
was imputed from linear regressions derived from the subgroup,
which related the actual operation undertaken with anaesthetic
time.
Fixed theatre cost was estimated by subtracting the total
variable costs (staffing and equipment costs) from the total
theatre cost in the patients who underwent the standard (open)
procedure. This fixed cost (d92.50) was then used with the
individual patient variable cost to determine patient specific
theatre cost.
Detailed records were taken of theatre staffing including
surgical/anaesthetic and nursing grades present for each operation.
Information from the sample was used to impute values for
patients in whom this information was not available by drawing a
random values from those in whom details were available,
stratified by operative procedure (open or lap) and operation
undertaken (open, lap or conversion). Use of disposable and
nondisposable equipment was estimated by the individual
surgeon’s normal practice for each procedure. Requirement for
blood and fluid transfusion was determined in the immediate
postoperative period and for 7 days following surgery, together
with blood volumes administered and type of blood used
(allogenic, autologous or blood products).
Hospital stay
Hospital stay was calculated from the date of operation to the date
of discharge/death plus an additional day (preoperative admis-
sion). This hospital stay was subdivided into time on the surgical
ward, time in intensive care (ICU) and time in high dependency
(HDU). As this analysis relates to follow-up to 3 months, in-patient
stay was truncated at 90 days.
Complications
Intraoperative complications were recorded in the immediate
postoperative period by the trial surgeon, and were subsumed
within the overall theatre costs. Postoperative complications were
recorded up to 30 days and 3 months postoperation. At these times
information was collected on whether further surgery was under-
taken. Follow-up questionnaires were sent to trial centres to
provide more detailed information on reoperations, including
anaesthetic time, additional in-patient stay for surgery and use of
ICU and/or HDU. Postoperative complications that did not lead to
further surgery were also recorded, and coded blind by a surgeon
to estimate resource use. Serious postoperative complications were
costed according to national figures, with account taken for in-
patient stay (NHS, 2002). Minor complications were coded
according to the need for antibiotics, urinary catheterisation and
CT scan.
Postdischarge health resource usage
Patients who agreed to take part in the health economics substudy
of the trial were sent questionnaires about their use of health
resources at both 2 weeks and 3 months postoperatively.
Information was requested on the number of in-patient days,
outpatient visits, general practitioner visits, use of district
(community) and stoma nursing services. Details of reasons for
visits were given, which allowed for exclusion of double counting
of in-patient stay (operative procedure and reoperations), and
outpatient visits for radiotherapy or chemotherapy, which were
excluded from the analysis.
UNIT COSTS
Unit costs were determined from a number of sources. Total
hourly rate for theatre time and recovery were provided by one of
the main hospitals participating, together with hotel cost for ward
stay, ICU/HDU and outpatient visit (Table 1). Staffing costs were
estimated as mid point of scales given in the UK literature (Netten
et al, 2001). Cost of theatre equipment specific to the procedures
undertaken were provided by a manufacturer, and given as the
average selling price for the products in 2003 (personal commu-
nication). All nonspecific equipment was assumed to be incorpo-
rated into the fixed theatre costs. Reoperations were assumed to be
open procedures, with variable hourly cost assumed to be identical
to the mean for patients who initially underwent open surgery.
Postdischarge health resource unit costs were also estimated from
national published figures (Netten et al, 2001). Indirect costs were
estimated by determining the time taken for the patients in work to
return to employment, with a cutoff set to 90 days. Average salary
costs of d66.24 per calendar day for those in full time employment
and d33.12 per day for part time workers were taken from the
Department of Work & Pensions for 2002.
Table 1 Key unit costs of resources used in the cost analysis
Unit Cost (d) Source
Theatre time Hour 577.00 A
Recovery Hour 124.00 A
Staffing
Consultant Hour 45.33 B
Specialist registrar Hour 28.49 B
Senior house officer Hour 24.47 B
House officer Hour 15.20 B
Nurse (F to I) Hour 18.55 B
Nurse (D to E) Hour 14.25 B
Nurse (A to C) Hour 9.16 B
Laparoscopic equipment
Scissors Unit 75.00 C
Grasper Unit 70.00 C
Trochar Unit 50.00 C
Ligaclip applicator Unit 105.00 C
Linear stapler Unit 105.00 C
Circular stapler Unit 225.00 C
Hospital stay
General ward (hotel) Day 154.00 A
HDU Day 918.00 A
ICU Day 1465.00 A
GP (home) Visit 47.00 B
GP (surgery) Visit 15.00 B
District nurse Visit 16.00 B
Stoma nurse Visit 16.00 B
A Leeds Hospitals NHS Trust. B PSSRU 2001. C Manufacturers’ average selling price
2003.
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Sensitivity analysis was used to challenge some of the
assumptions made in the analysis, with particular respect to
perioperative costs, equipment costs, recovery time, ICU cost and
cost of hospital stay (ward/ICU/HDU). In this analysis a potential
deviation from the assumed costs of 20% either side of the
estimated costs was used to determine the robustness of the cost
estimates. Analysis was also undertaken analysing patients with
rectal and colon disease separately.
Average costs were determined with bootstrap estimates of
confidence intervals given at 2.5 and 97.5% levels.
RESULTS
Of the total patients included in this trial, 696 agreed to take part in
the health economics substudy. A further 14 were excluded on the
basis that details of the operative procedure were unknown at the
time of analysis, leaving a total of 682 (452 laparoscopic, 230 open).
Of these, 315 underwent a successful laparoscopic procedure (311
randomised to lap, four randomised to open), with 122 of the 437
(28%) patients requiring a conversion to open procedure. In all,
242 underwent a standard open procedure (17 randomised to lap,
225 randomised to open). A further three patients had no surgery.
Table 2 details baseline demographics for all patients included in
the health economics substudy, while Table 3 presents key items of
resource use for these patients. As expected, patients in the lap
group had longer median duration anaesthetic time (180 vs
135min), but slightly shorter median stay in hospital (10.0 vs 12.0
days). Intensive care was more frequently required for patients
randomised to the open procedure, but the mean duration in ICU
was shorter. A similar proportion of randomised patients required
blood transfusion (33.6 vs 34.0%).
For the 233 patients included in the detailed theatre resource use
subgroup, time in theatre was longer for the laparoscopic group
compared with the open group (median 165 vs 115min), Table 3.
Theatre staffing was similar between procedures, for all grades of
medical and nursing staff.
The incidence of reoperations within 3 months after surgery was
similar between groups (10.6% for the lap group vs 9.1% for the
open group), Table 4. The incidence of major complications was
similar between the randomised groups (14.4% for the lap group vs
10.7% for the open group), as were the proportion of patients
experiencing minor complications requiring antibiotics, urinary
catheterisation and CT scans.
Over the 3 month postoperative period patients were seen by a
wide range of health care professionals for numerous reasons.
After 3 months 20.3% lap patients and 32.1% of open patients
underwent a further in-patient stay (for any reason), with 75.0%
lap patients and 50.8% open patients were seen as outpatients for
reasons other than radiotherapy or chemotherapy. The stoma
nurse saw 38.7% lap patients and 45.2% open patients (mean
Table 2 Demographics of patients entered into the health economics
sub-study of the CLASICC Trial
Lap Open
n 452 230
Gender
Male 255 (56.4%) 131 (56.9%)
Female 197 (43.6%) 99 (43.0%)
Age in years
Mean (s.d.) 68.10 (10.48) 68.80 (11.86)
WHO performance status
0 298 (65.9%) 135 (59.0%)
1 110 (24.3%) 71 (31.0%)
2 38 (8.4%) 22 (9.6%)
3 5 (1.1%) 1 (0.4%)
4 1 (0.2%) 0
Missing 0 1
Surgery undertaken
Laparoscopic 311 (68.8%) 4 (1.7%)
Open 17 (3.8%) 225 (97.8%)
Conversion 122 (30.0%) 0 (0)
No operation 2 (0.4%) 1 (0.4%)
Site of tumour
Colon 230 (50.9%) 118 (51.3%)
Rectum 222 (49.1%) 112 (48.7%)
Table 3 Key items of resource use
Total group Laparoscopic group Open group
N 452 230
Laparoscopic 311 4
Open 17 225
Conversion 122 0
No operation 2 1
Duration of anaesthetic
Mean 183.7 139.7
Median (IQR) 180.0 (135.0–225.0) 135.0 (100.0–180.0)
Total 420 209
Total length of hospital stay (days)
Mean 13.6 14.4
Median (IQR) 10.0 (8.0–15.0) 12.0 (9.0–15.5)
Total 424 213
Intensive care n (%) 19 (5.4%) 17 (9.9%)
354 171
For ICU stay
Mean 5.74 1.84
Median (ICR) 3.0 (2.0–5.0) 1.33 (1.0–2.0)
High Dependency n (%) 46 (14.0%) 19 (12.0%)
328 158
For HDU stay
Mean 2.71 3.55
Median (IQR) 2.0 (2.0–3.25) 3.0 (2.0–4.0)
Blood transfusion n (%) 143 (33.6%) 72 (34.0%)
426 212
Allogenic blood 142 (33.3%) 72 (34.0%)
426 212
Blood products 3 (0.7%) 5 (2.3%)
426 213
Subgroup Laparoscopic Open
N 145 88
Time in anaesthetic room
Mean 21.0 18.2
Median (IQR) 19.0 (14.0–25.0) 15.0 (10.0–23.0)
143 81
Time in theatre in minutes
Mean 172.3 118.2
Median (IQR) 165.0 (124.0–210.0) 115.0 (83.0–140.0)
142 79
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number of visits 4.5 vs 4.8). District nurses were seen by 48.7% of
lap and 77.4% open patients.
Three Month cost of health resources
Table 5 gives the overall cost of health resource use of patients who
entered the health economics substudy of the CLASICC trial. The
results indicate that patients randomised to laparoscopic surgery
had a significantly higher cost around the perioperative period
(mean difference¼ d317.96, 95%CI d235.39 to d395.66), however,
the total cost was similar, with the laparoscopic arm having slightly
higher total cost (mean difference¼ d268.11, 95%CI d689.09 to
d1457.52). Sensitivity analysis was used to challenge some of the
assumptions made in the analysis, (Table 6). While some changes
did occur with respect to the mean difference in cost, patients who
underwent laparoscopic surgery had consistently higher costs
associated with their procedure and follow-up. The largest
difference occurred when hospital costs were challenged (d317)
with smallest differences occurring with reduced equipment costs
(d86).
Table 7 gives details of cost differences associated with colon
and rectal cancers analysed separately. The cost of rectal surgery
was higher than for colon, for both lap (d8260 vs d5587) and open
procedures (d7820 vs d5503). Again the difference between
randomised groups indicated a slightly higher cost for laparo-
scopic surgery than the open procedure, with a smaller difference
for colon cancers (d83.92, 95%CI d642.12 to d791.99) compared
with rectal cancer (d439.15, 95%CI d1293.85 to d2857.27).
Analysis was undertaken to examine the relationship between
conversion rate and total cost of care. The relationship between the
two was not a simple one (Table 8). Conversion rates varied
between 36.1% in the second year of randomisation up to 17% in
Table 4 Postoperative complications and use of resources
Laparoscopic Open
N
Reoperations within 3 months 48 (10.6%) 21 (9.1%)
Surgical complication 34 17
Other complication 8 2
Stoma surgery 6 2
Postoperative complications (excluding reoperations)
Major complication 62 (14.4%) 23 (10.7%)
431 215
Other complication
Requiring antibiotics 67 (15.5%) 38 (17.7%)
431 215
Other complication
Requiring urinary catheterisation 12 (2.8%) 11 (5.1%)
431 215
Other complication 13 (3.0%) 5 (2.3%)
Requiring CT scan 431 215
Community Health Services (up to 3 months)
All cause
GP (surgery) visits
Yes 202 (44.7%) 120 (52.2%)
No 250 110
Range (1–15) (1–7)
GP (home)
Yes 206 (45.6%) 88 (38.3%)
No 246 142
Range (1–10) (1–11)
Stoma nurse visits
Yes 175 (38.78%) 104 (45.2%)
No 277 126
Range (1–17) (1–17)
District nurse visits
Yes 146 (48.7%) 178 (77.4%)
No 154 52
Range (1–104) (1–66)
Table 5 Average cost of care for randomised patients (UK pounds)
Laparoscopic Open
n¼452 n¼ 230
Mean Mean Difference (95%CI)
Theatre 1703.94 1385.98 317.96 (235.39 to 395.66)
Staffing 472.47 357.93
Equipment 512.32 331.08
Blood 91.45 112.71
Other 627.70 584.26
Hospital costs 2930.69 3176.52 245.83 (678.31 to 188.07)
ITU/HDU 1030.98 1200.70
Ward 1899.71 1975.82
Chemo/
radiotherapy
279.76 318.65 38.89 (124.35 to 36.31)
Reoperations and
other
complications
762.08 553.11 208.97 (331.14 to 1087.19)
Theatre 252.35 254.54
ITU/HDU 372.73 0.0
Ward 88.58 266.49
Complications 48.41 32.08
Community
health
190.48 203.44 12.96 (54.56 to 1.05)
Indirect costs 1032.66 993.81 38.85 (305.82 to 389.35)
Total 6899.63 6631.52 268.11 (689.09 to 1457.52)
Confidence intervals generated by bootstrap method (1000) iterations, and given for
2.5% and 97.5% percentiles.
Table 6 Sensitivity analysis
Cost difference (Lap-open) 95%CI
Base case 268.11 689.09 to 1457.52
Perioperative costs
20% 204.52 701.10 to 1439.96
+20% 331.71 659.03 to 1465.03
Equipment costs
20% 86.87 817.58 to 1364.69
+20% 218.95 764.58 to 1477.99
Recovery cost
20% 266.55 597.54 to 1487.66
+20% 269.67 662.85 to 1456.99
ICU cost
20% 237.54 641.61 to 1364.71
+20% 298.68 638.13 to 1530.53
Hospital costs (Ward, ITU, HDU)
20% 317.27 593.31 to 1427.99
+20% 218.95 840.25 to 1504.95
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the sixth year. Despite this, the overall difference between
randomised groups was greatest in the sixth year in favour of
the open procedure, with years one and two (highest conversion
rates), experiencing costs in favour of laparoscopic surgery. This
apparent anomaly was explored by examination of actual
operation performed. The cost of undertaking a successful
laparoscopic procedure was highest in the sixth year (d7713.22),
whereas the conversion costs were lowest (d5798.06). Lowest cost
of a successful laparoscopic procedure was in year 2 (d5682.57)
which also corresponded with a high cost of conversion
(d8643.82).
DISCUSSION
The CLASICC trial has a pragmatic approach to determine the
outcomes of laparoscopic surgery compared with open procedures
in patients with colorectal cancer. It has shown that there is a trade
off in costs. The laparoscopic procedure was more expensive in
terms of theatre costs, whilst the other hospital costs such as ward,
ICU and HDU and complications were higher in the patients
randomised to the open procedure.
The results of this trial are consistent with other costing studies
of laparoscopic surgery for colorectal cancer (Philipson et al, 1997,
Khalili et al, 1998, Delaney et al, 2003, Janson et al, 2004). Khalili
et al (1998) found similar costs between treatment groups, though
the operating theatre costs were higher for laparoscopic surgery.
While others have found overall higher costs of the laparoscopic
procedure, much of this can be explained by the results being
limited to operating costs only (Philipson et al, 1997). Delaney at
al used a case matched design to compare patients who underwent
colorectal surgery using the laparoscopic and open procedures.
Patients were matched for age, gender and disease group. Their
conclusion was that laparoscopic surgery was less expensive than
the open procedure despite a higher overall cost within the
operating room. This was largely a consequence of shorter hospital
stay (3 vs 6 days) and lower ward nursing, pharmacy and
laboratory costs. However, of the 150 matched cases in this study
only 34 laparoscopic and 47 open surgery patients were operated
on for colon cancer, and information was only provided for
patients while they were within the hospital system.
The recent COLOR trial has provided a similar approach to the
analysis of short-term costs undertaken in the current trial, with a
sample of 210 Swedish patients from a multinational trial of 1200
patients with colon cancer (Janson et al, 2004). Societal costs were
higher in the patients who underwent conventional open surgery,
although as expected operative costs were higher in patients who
underwent laparoscopic surgery. The total 12-week costs were
significantly higher in the laparoscopic group (difference¼ h2244),
despite just 14 of 98 (14%) undergoing intraoperative conversion
from lap to open. Their results indicated that laparoscopic surgery
was not associated with shorter hospital stay, and required more
reoperations. Conversely the present trial results demonstrated
similar costs between groups, despite there being a higher
conversion rate (28%). The present study also indicated a slightly
lower duration in hospital for the patients randomised to
laparoscopic surgery (13.6 vs 14.4 days), which would reduce
costs in favour of the laparoscopic procedure.
Table 7 Average cost of care for colon and rectal cancer patients (UK
pounds)
Laparoscopic Open
n¼ 230 n¼118
Mean Mean Difference (95% CI)
Colon
Theatre 1596.14 1327.41 268.73 (172.91 to 371.01)
Hospital 2517.22 2666.98 149.76 (594.34 to 316.56)
Chemo/radiotherapy 185.41 174.49 10.92 (70.58 to 84.26)
Reoperations/ 192.22 397.36 205.14 (464.25 to 31.58)
Other complications
Community services 149.54 162.24 12.70 (57.10 to 8.07)
Indirect costs 946.39 774.52 171.87 (277.54 to 590.89)
Total 5586.93 5503.01 83.92 (642.12 to 791.99)
Laparoscopic Open
n¼ 222 n¼112
Mean Mean Difference (95% CI)
Rectum
Theatre 1815.64 1447.69 367.95 (243.54 to 483.57)
Hospital 3359.07 3713.37 354.30 (1131.86 to 366.54)
Chemo/radiotherapy 377.51 470.53 93.02 (228.04 to 41.38)
Reoperations/ 1352.48 717.21 635.27 (351.21 to 2297.64)
Other complications
Community services 232.88 246.83 13.95 (76.66 to 38.83)
Indirect costs 1112.04 1224.84 102.80 (576.04 to 367.67)
Total 8259.64 7820.49 439.15 (1293.85 to 2857.27)
Confidence intervals generated by bootstrap method (1000) iterations, and given for
2.5 and 97.5% percentiles.
Table 8 Average cost of care for randomised groups and actual operation performed according to year of trial entry
Year Conversion rate (%) Laparoscopic Mean Open mean Difference (95% CI)
Randomised groups
1 33.3 6850.49 7009.81 –159.32 (1806.17 to 1500.76)
2 36.1 6711.46 7041.89 330.43 (2095.52 to 1551.85)
3 28.6 6523.52 6447.73 75.79 (1428.62 to 1535.70)
4 29.0 7098.15 6845.17 252.98 (1522.74 to 1946.65)
5 29.6 6847.73 6362.10 485.63 (1172.42 to 2233.04)
6 17.0 7309.22 6268.21 1041.01 (1790.83 to 5232.97)
Conversion rate (%) Successful lap mean Conversion mean Open mean
Actual operation performed
1 33.3 6151.12 7623.27 7365.22
2 36.1 5682.57 8643.82 6939.80
3 28.6 5942.37 7876.73 6496.02
4 29.0 6339.70 9238.64 6656.42
5 29.6 6296.47 8380.52 6238.77
6 17.0 7713.22 5798.06 6167.66
Confidence intervals generated by bootstrap method (1000) iterations, and given for 2.5% and 97.5% percentiles.
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The results show a clear difference in cost between patients
who undergo colon cancer resection and those with rectal disease.
The overall cost difference of undertaking laparoscopic cancer in
rectal cancer was somewhat higher than for patients who under-
went colon cancer resection. Despite these differences, the
percentage cost difference was only around 5% of the total cost
of care.
The apparent paradox in relation to the difference in costs in
relation to conversion rate can be explained by observing the costs
of each operation type undertaken. There was evidence that the
cost of open surgery was reducing over time as a consequence of
shorter hospital stay and less use of HDU. However, the cost of a
successful laparoscopic operation was increasing despite a lower
conversion rate. This may be a consequence of surgeons spending
more time and effort in completing the operation they had
originally planned, with a subsequent increase in cost for this
group. Evidence to support this comes from an analysis of
reoperation costs, which increased from an average of d321 in year
one to d2119 in year 6.
CONCLUSION
The analysis of cost data from 682 patients from the CLASICC trial
has shown that there are similar costs involved in the laparoscopic
and open procedures for colorectal cancer within the UK. On the
basis that the short-term outcomes are similar, it would appear
that until longer-term results for the randomised trials are made
available, it would appear that both surgical options are equally
acceptable in the short-term for both clinical and costs of
treatment.
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